CURE Today

Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.

[CURE Today @cure_today]

AI is changing breast cancer care and newer technology can analyze mammograms to help estimate a person’s risk of developing breast cancer in the future.

For more visit: https://t.co/H1iM0hIrYx

[CURE Today @cure_today]

The FDA granted accelerated approval to Etcamah (camizestrant) for certain HR-positive, HER2-negative breast cancers with ESR1 mutations. Learn what this approval means for patients. https://t.co/jTJdfFwULk

[CURE Today @cure_today]

Endurance athlete Eric Gelber has spent 20 years pushing his physical limits to fund multiple myeloma research. He's back at it with another ambitious fitness challenge: https://t.co/Ikbhg5Paoj

[CURE Today @cure_today]

🎙️ CURE Talks Cancer is returning!

We’re kicking off the podcast relaunch with Rob Lowe, actor, producer and cancer advocate.

Hear conversations and perspectives from across the cancer community.

🎧 New episode coming soon!
#CURETalksCancer

[CURE Today @cure_today]

The FDA has approved BESREMi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia (ET) — marking the first new treatment for this rare blood cancer in nearly 30 years. https://t.co/tVkMXiPMzj

[CURE Today @cure_today]

The FDA approved Rasonque (daraxonrasib) for patients with metastatic pancreatic cancer.

CURE spoke with Dr. Kristin Higgins of City of Hope Atlanta about what patients should know about this new treatment.

Read the full Q&A here! https://t.co/lCb7v3puzt

[CURE Today @cure_today]

With the FDA approval of daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma, oncology nurses play a critical role in managing patient adherence and navigating key toxicities: https://t.co/B4NshH4sZx #PancreaticCancer #FDAApproval #Daraxonrasib #Rasonque #CancerCare

[CURE Today @cure_today]

🚨 FDA Approval: The FDA has approved Rasonque (Daraxonrasib), a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma.

Learn More: https://t.co/iXlyR2SlzK

[CURE Today @cure_today]

Dr. Andrew Silverman of the Pediatric Hematology Oncology Group at Jersey Shore University Medical Center sat down with CURE® to answer the questions parents fear most.
https://t.co/NSKyD0LqWE

[CURE Today @cure_today]

Ziihera just landed a big first-line FDA approval: paired with Tevimbra + chemo for HER2-positive gastroesophageal cancer regardless of PD-L1 status, or with chemo alone for strongly HER2-positive disease.

Read more: https://t.co/JvZ5GYlsS9

[CURE Today @cure_today]

🧬 A cancer treatment made from your own tumor's DNA just hit a major milestone. In a new Phase 3 trial, adding the personalized mRNA therapy intismeran autogene to Keytruda reduced the risk of melanoma coming back after surgery.
https://t.co/tM9hrKlH2J

[CURE Today @cure_today]

A new option for multiple myeloma: the FDA has approved Zenbexus (iberdomide), a once-daily pill, in combination with three other medicines for adults whose myeloma has already been treated at least once.

Read the full article: https://t.co/elUuNN3Q8y

#MultipleMyeloma

[CURE Today @cure_today]

In our latest Text a Survivor, Sally Kalksma answers the questions patients ask most, from what "incurable but treatable" really means to what she wishes she'd known before her transplant. https://t.co/dEs9B0Bfkv

#MultipleMyeloma #Myeloma #TextASurvivor

[CURE Today @cure_today]

How can you make informed bladder cancer treatment decisions? Join Dr. Ashish Kamat for the @power4patients ELEVATE webinar on patient education, shared decision-making, and advocacy.

📅 September 1, 2026
🕐 1 PM ET

Learn more and register here: https://t.co/ZGQOBjpmUO

[CURE Today @cure_today]

The FDA has approved Tudriqev plus Opdivo for adults with unresectable advanced cutaneous melanoma that has progressed after PD-1 immunotherapy. #Melanoma #SkinCancer
https://t.co/cmfKuITfYO

[CURE Today @cure_today]

🚨 FDA approval: Pluvicto plus hormone therapy is now approved for certain adults with PSMA-positive metastatic prostate cancer

Learn More: https://t.co/v2aEdJbtOn

[CURE Today @cure_today]

Wildfire smoke is blanketing much of the U.S. right now — and if you or a loved one has been affected by cancer, it's worth knowing what the research says. #CancerCare #LungCancer #WildfireSmoke #AirQuality #CancerAwareness #Oncology
https://t.co/xjWFTyvgnn

[CURE Today @cure_today]

The FDA has approved Revtorpyk with fulvestrant, with or without Ibrance, for adults with HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation that has progressed after endocrine therapy. #BreastCancer
https://t.co/4P7LdQLlrX

[CURE Today @cure_today]

🚨 FDA Approval 🚨

FDA approves Retevmo (selpercatinib), a cancer drug for ages 2+, targeting tumors from a specific gene change — no matter where they started. Nearly half of patients responded, with effects lasting about 2 years for many!

Learn more: https://t.co/7rdcYooWRL

[CURE Today @cure_today]

Keytruda (pembrolizumab) or Keytruda Qlex combined with Padcev (enfortumab vedotin-ejfv) is now approved for adults with muscle-invasive bladder cancer who are eligible for surgery — before and after bladder removal.
🔗https://t.co/wJaNWZreFe